Results Healthcare has advised Bioscript on its acquisition of Fortis Pharma Consulting and Valid Insight
- Service: M&A
- Sector: Healthcare
- Sub Sector: Pharma Commercialisation Services
- Engagement Type: Buy Side
Results Healthcare is delighted to announce that it has advised Bioscript, a successful global provider of medical communications and regulatory writing services for pharmaceutical companies, on its acquisition of both Fortis Pharma Consulting, a specialist medical affairs services provider, and Valid Insight, a specialist market access consultancy. Sovereign Capital Partners backed the Bioscript management team earlier this year to further develop and grow the business – a transaction also advised by Results.
Established in 2005, Fortis is a highly successful business that works with clients in refining and articulating a product’s value at launch, with specialist skills in medical education, expert engagement and strategic consultancy. The business supports access teams from smaller healthcare organisations through to leading multi-nationals.
Founded in 2016, Valid Insight is an award-winning consultancy working with clients to deliver pricing, reimbursement, market access and payer value communication strategies through the full product development cycle, supporting optimal patient access to new and innovative health technologies.
The addition of these specialist global providers strengthens Bioscript’s end-to-end service offering by extending the breadth and depth of its services across the pharmaceutical product lifecycle, and by bringing additional capabilities in medical affairs, global market access strategy and payer value communications. The combined group has a staff of 135, which includes a large team of highly skilled specialist technical consultants and brings additional top 20 global pharma company clients.
Fortis and Valid Insight are two fantastic businesses which are a great fit for Bioscript, and bring a wealth of expertise which perfectly complements our own rich scientific heritage. The acquisitions will enable us to build upon Bioscript’s extensive, integrated services at a time when increasing trial complexity, greater evidence requirements from regulators and payers, as well as pricing pressures, require a fully joined-up cross-functional approach.
Founder & CEO, Bioscript